Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Experimental evolution study using in vitro and ex vivo models to characterize an adapted phage variant; no animal infection efficacy data, clinical outcomes, or in vivo proof of concept reported.
Historical commentary confirming antidepressant-like effects of valproic acid in rodent models first demonstrated in the 1980s, supporting recent meta-analytic findings but not providing new primary evidence.
This is a narrative review synthesizing prior literature on S. suis serotype 2 virulence mechanisms; it raises questions and organizes existing knowledge rather than reporting new experimental evidence or clinical outcomes.
A mechanistic study in cell and transgenic mouse models showing FGF17 delivery reduces Aβ deposition and apoptosis with pathway confirmation, but lacking human efficacy data and powered clinical outcomes.
A controlled preclinical study in an animal AD model showing reversal of multiple network and molecular abnormalities with 40 Hz stimulation; sound design but limited to rodents and requires confirmation in humans.
Mechanistically-supported preclinical evidence in diet-induced obese mice demonstrates metabolic and inflammatory benefits with a putative pathway (kynurenine reduction), but lacks human efficacy data and comparative controls needed for strong or practice-changing classification.
This is a preclinical mechanistic study developing a novel transgenic tracking platform in mice, demonstrating proof-of-concept for labeling degenerating neurons but lacking clinical translation or therapeutic outcome data.
First in vivo characterization of spike-LFP coupling in AD model with single-arm intervention study; mechanistic findings in transgenic mice require confirmation in larger, controlled trials before clinical translation.